Phathom Pharmaceuticals, Inc.
PHAT
$12.56
$0.030.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 204.89M | 175.11M | 147.19M | 114.04M | 81.86M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 204.89M | 175.11M | 147.19M | 114.04M | 81.86M |
| Cost of Revenue | 30.87M | 22.60M | 18.77M | 14.93M | 11.27M |
| Gross Profit | 174.02M | 152.51M | 128.42M | 99.11M | 70.59M |
| SG&A Expenses | 239.25M | 279.72M | 308.03M | 332.57M | 323.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 301.49M | 335.10M | 360.67M | 383.04M | 368.24M |
| Operating Income | -96.60M | -159.99M | -213.48M | -269.00M | -286.38M |
| Income Before Tax | -157.30M | -221.25M | -274.55M | -330.15M | -345.79M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -157.30 | -221.25 | -274.55 | -330.15 | -345.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -157.30M | -221.25M | -274.55M | -330.15M | -345.79M |
| EBIT | -96.60M | -159.99M | -213.48M | -269.00M | -286.38M |
| EBITDA | -96.03M | -159.35M | -212.78M | -268.27M | -285.62M |
| EPS Basic | -2.11 | -3.05 | -3.81 | -4.73 | -5.24 |
| Normalized Basic EPS | -1.32 | -1.91 | -2.38 | -2.96 | -3.28 |
| EPS Diluted | -2.11 | -3.05 | -3.81 | -4.73 | -5.24 |
| Normalized Diluted EPS | -1.32 | -1.91 | -2.38 | -2.96 | -3.28 |
| Average Basic Shares Outstanding | 301.73M | 291.65M | 288.88M | 280.11M | 266.20M |
| Average Diluted Shares Outstanding | 301.73M | 291.65M | 288.88M | 280.11M | 266.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |